Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Chief Executive Officer Neil Clark steps down immediately to. | May 25, 2023
Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology - Pretax loss widens to GBP7.7 million for 2022 from GBP6.3 million in 2021. Administrative expenses increase to GBP7.4. | April 13, 2023
Destiny Pharma PLC on Wednesday said it has finalised development plans for phase three testing of its late-stage clinical asset, XF-73 Nasal, which aims to prevent post-surgical staphylococcal. | December 7, 2022